Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)

The FDA guidance for industry in the premarketing clinical evaluation of drug-induced liver injury (DILI) is the most specific regulatory guidance currently available and has been useful in setting standards for the great majority of clinical indications involving subjects with a low risk of liver d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kullak-Ublick, Gerd A., Merz, Michael, Griffel, Louis, Kaplowitz, Neil, Watkins, Paul B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212149/
https://www.ncbi.nlm.nih.gov/pubmed/25352328
http://dx.doi.org/10.1007/s40264-014-0186-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212149/
https://www.ncbi.nlm.nih.gov/pubmed/25352328
http://dx.doi.org/10.1007/s40264-014-0186-3

Ejemplares similares